| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Animal: DNA Viruses |
Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología, CSIC, Campus Universidad Autónoma, E-28049 Madrid, Spain1
Author for correspondence: Mariano Esteban. Fax +34 91 585 4506. e-mail mesteban{at}cnb.uam.es
The WHO smallpox eradication program was concluded 21 years ago and the non-vaccinated population is now at risk of poxvirus infections, either by contact with monkeypox or through bioterrorism. Since drugs specific against poxvirus infections are limited, neutralizing monoclonal antibodies (mAbs) that are effective in vivo may be an important tool in controlling poxvirus infections. To this end, we studied the efficacy of the mAb C3, reactive against the trimeric 14-kDa protein of vaccinia virus (VV) localized in the membrane of the intracellular form of mature virus, for its ability to neutralize VV infection in mice. The results show that prophylactic as well as therapeutic administration of mAb C3 can be an effective means of control of VV replication within the host. The interval of antibody efficacy following a single administration, before and after VV inoculation, has been defined. This study reinforces the notion that neutralizing mAbs should be developed to control health-related human infections by poxviruses.
This article has been cited by other articles:
|
|
 |
|
  M. R.-E.-I. Benhnia, M. M. McCausland, J. Laudenslager, S. W. Granger, S. Rickert, L. Koriazova, T. Tahara, R. T. Kubo, S. Kato, and S. Crotty Heavily Isotype-Dependent Protective Activities of Human Antibodies against Vaccinia Virus Extracellular Virion Antigen B5 J. Virol., December 1, 2009; 83(23): 12355 - 12367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Oyoshi, A. Elkhal, L. Kumar, J. E. Scott, S. Koduru, R. He, D. Y. M. Leung, M. D. Howell, H. C. Oettgen, G. F. Murphy, et al. Vaccinia virus inoculation in sites of allergic skin inflammation elicits a vigorous cutaneous IL-17 response PNAS, September 1, 2009; 106(35): 14954 - 14959. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R.-E.-I. Benhnia, M. M. McCausland, J. Moyron, J. Laudenslager, S. Granger, S. Rickert, L. Koriazova, R. Kubo, S. Kato, and S. Crotty Vaccinia Virus Extracellular Enveloped Virion Neutralization In Vitro and Protection In Vivo Depend on Complement J. Virol., February 1, 2009; 83(3): 1201 - 1215. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. N. Fogg, J. L. Americo, P. L. Earl, W. Resch, L. Aldaz-Carroll, R. J. Eisenberg, G. H. Cohen, and B. Moss Disparity between Levels of In Vitro Neutralization of Vaccinia Virus by Antibody to the A27 Protein and Protection of Mice against Intranasal Challenge J. Virol., August 15, 2008; 82(16): 8022 - 8029. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Berhanu, R. L. Wilson, D. L. Kirkwood-Watts, D. S. King, T. K. Warren, S. A. Lund, L. L. Brown, A. K. Krupkin, E. VanderMay, W. Weimers, et al. Vaccination of BALB/c Mice with Escherichia coli-Expressed Vaccinia Virus Proteins A27L, B5R, and D8L Protects Mice from Lethal Vaccinia Virus Challenge J. Virol., April 1, 2008; 82(7): 3517 - 3529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R.-E.-I. Benhnia, M. M. McCausland, H.-P. Su, K. Singh, J. Hoffmann, D. H. Davies, P. L. Felgner, S. Head, A. Sette, D. N. Garboczi, et al. Redundancy and Plasticity of Neutralizing Antibody Responses Are Cornerstone Attributes of the Human Immune Response to the Smallpox Vaccine J. Virol., April 1, 2008; 82(7): 3751 - 3768. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Chen, P. Earl, J. Americo, I. Damon, S. K. Smith, F. Yu, A. Sebrell, S. Emerson, G. Cohen, R. J. Eisenberg, et al. Characterization of Chimpanzee/Human Monoclonal Antibodies to Vaccinia Virus A33 Glycoprotein and Its Variola Virus Homolog In Vitro and in a Vaccinia Virus Mouse Protection Model J. Virol., September 1, 2007; 81(17): 8989 - 8995. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Tang, M. Murtadha, M. Schnell, L. C. Eisenlohr, J. Hooper, and P. Flomenberg Human T-cell responses to vaccinia virus envelope proteins. J. Virol., October 1, 2006; 80(20): 10010 - 10020. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Lustig, C. Fogg, J. C. Whitbeck, R. J. Eisenberg, G. H. Cohen, and B. Moss Combinations of Polyclonal or Monoclonal Antibodies to Proteins of the Outer Membranes of the Two Infectious Forms of Vaccinia Virus Protect Mice against a Lethal Respiratory Challenge J. Virol., November 1, 2005; 79(21): 13454 - 13462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Davies, M. M. McCausland, C. Valdez, D. Huynh, J. E. Hernandez, Y. Mu, S. Hirst, L. Villarreal, P. L. Felgner, and S. Crotty Vaccinia Virus H3L Envelope Protein Is a Major Target of Neutralizing Antibodies in Humans and Elicits Protection against Lethal Challenge in Mice J. Virol., September 15, 2005; 79(18): 11724 - 11733. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Law, M. M. Putz, and G. L. Smith An investigation of the therapeutic value of vaccinia-immune IgG in a mouse pneumonia model J. Gen. Virol., April 1, 2005; 86(4): 991 - 1000. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Hooper, E. Thompson, C. Wilhelmsen, M. Zimmerman, M. A. Ichou, S. E. Steffen, C. S. Schmaljohn, A. L. Schmaljohn, and P. B. Jahrling Smallpox DNA Vaccine Protects Nonhuman Primates against Lethal Monkeypox J. Virol., May 1, 2004; 78(9): 4433 - 4443. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. L. Smith, A. Vanderplasschen, and M. Law The formation and function of extracellular enveloped vaccinia virus J. Gen. Virol., December 1, 2002; 83(12): 2915 - 2931. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
